How big is the Duchenne Muscular Dystrophy Treatment Market?

The Duchenne Muscular Dystrophy Treatment Market size is expected to reach USD 3.42 billion in 2024 and grow at a CAGR of 19.13% to reach USD 8.19 billion by 2029. Read More

What is the current Duchenne Muscular Dystrophy Treatment Market size?

In 2024, the Duchenne Muscular Dystrophy Treatment Market size is expected to reach USD 3.42 billion. Read More

Who are the key players in Duchenne Muscular Dystrophy Treatment Market?

NIPPON SHINYAKU CO., LTD. (NS Pharma Inc.), ITALFARMACO S.p.A., PTC Therapeutics, Santhera Pharmaceuticals and Sarepta Therapeutics are the major companies operating in the Duchenne Muscular Dystrophy Treatment Market. Read More

Which is the fastest growing region in Duchenne Muscular Dystrophy Treatment Market?

Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029). Read More

Which region has the biggest share in Duchenne Muscular Dystrophy Treatment Market?

In 2024, the North America accounts for the largest market share in Duchenne Muscular Dystrophy Treatment Market. Read More

What years does this Duchenne Muscular Dystrophy Treatment Market cover, and what was the market size in 2023?

In 2023, the Duchenne Muscular Dystrophy Treatment Market size was estimated at USD 2.77 billion. The report covers the Duchenne Muscular Dystrophy Treatment Market historical market size for years: 2021, 2022 and 2023. The report also forecasts the Duchenne Muscular Dystrophy Treatment Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029. Read More

Duchenne Muscular Dystrophy Treatment Market Share

Statistics for the 2023 & 2024 Duchenne Muscular Dystrophy Treatment market share, created by Mordor Intelligence™ Industry Reports. Duchenne Muscular Dystrophy Treatment share report includes a market forecast to 2029 and historical overview. Get a sample of this industry share analysis as a free report PDF download.

Market Share of Duchenne Muscular Dystrophy Treatment Industry

The Duchenne muscular dystrophy treatment market is moderately fragmented and consists of several major players. Some companies currently dominating the market are Nippon Shinyaku Co. Ltd, ITALFARMACO SpA, PTC Therapeutics, Santhera Pharmaceuticals Holding AG, and Sarepta Therapeutics Inc.